ArticleClinical and experimental hepatology2026
Potential role of NLRP3 genetic polymorphism and gene expression in differentiating causes of neonatal cholestasis.
Article in Clinical and experimental hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: It has long been a focus of research to differentiate among the various causes of neonatal cholestasis, particularly biliary atresia (BA) from non-BA. The NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome's role in the pathophysiology of BA is becoming increasingly clear. However, animal models served as the foundation for most of this research. As it is important to diagnose BA as early as possible for a favorable prognosis, the current investigation aimed to investigate the function of NLRP3 rs10754558 and Material and methods: The study included 21 patients with BA, 24 patients with neonatal cholestasis due to causes other than BA, and 20 healthy infants as the control group. A clinical evaluation and standard laboratory testing were conducted on each participant. NLRP3 rs10754558 and Results: A significant difference in NLRP3 rs10754558 was observed between the BA and non-BA groups in the general genotype model ( Conclusions: In conclusion, NLRP3 rs10754558 may contribute to non-BA neonatal cholestasis in ways other than by influencing gene expression levels. However, in non-BA patients, NLRP3 expression levels may improve coagulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.